Company Overview and News

1
UPDATE 1-Hesperia hires JP Morgan as adviser on NH Hoteles stake

2018-09-04 reuters
MADRID (Reuters) - Spanish hotel group Hesperia has hired JP Morgan to advise on options for its 8 percent stake in domestic peer NH Hoteles, currently the target of a takeover offer from Thai firm Minor International, two sources familiar with the matter said.
H NHH

 
HOTEL anuncia cambio de título de Directivos

2018-07-19 globenewswire
CIUDAD DE MÉXICO, July 19, 2018 (GLOBE NEWSWIRE) -- Grupo Hotelero Santa Fe, S.A.B. de C.V. (BMV:HOTEL) (“HOTEL” o “la Compañía”), una de las empresas líderes de la industria hotelera en México, anuncia al público inversionista los siguientes cambios en su Equipo Directivo:
NHH

3
Blackstone Becomes Spain’s Biggest Hotel & Property Owner

2018-06-15 wolfstreet
Private equity firm Blackstone, the undisputed king of property funds, continues to bet big on global real estate. In the last week it raised $9.4 billion for Asian real estate. It was also given the green light to acquire Spain’s biggest real estate investment fund (REIT), Hispania, for €1.9 billion. The move, after its prior acquisitions, will cement its position as Spain’s biggest hotel owner and fully private landlord.
BNC BPESY BPESF SANT NHH SAN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to MADX:NHH / Nh Hoteles on message board site Silicon Investor.

A Diversified Environmental Company ... CNHH A Diversified Environmental Company ... CNHH A Diversified Environmental Company ... CNHH CNHH C.N.H. Holdings ... Gas u0026 Oil / Service CNHH C.N.H. Holdings ... Gas u0026 Oil / Service CNHH C.N.H. Holdings ... Gas u0026 Oil / Service
CNHH ... Greece Shipping Company CNHH ... Greece Shipping Company CNHH ... Greece Shipping Company